Resultados de la búsqueda

Sanz J, Fuster V. Update in Cardiology. Ann Intern Med (2010) 152:786-91

Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol (2010) 55:1487-98

Zaitsev S, Spitzer D, Murciano JC, Ding BS, Tliba S, Kowalska MA, Marcos-Contreras OA, Kuo A, Stepanova V, Atkinson JP, Poncz M, Cines DB, Muzykantov VR. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 115:5241-8

Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol (2009) 53:2315-23

Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med (2009) 6:101-10

Farkouh ME and Fuster V. Diabetes and aspirin: beware of underpowered negative trials. Nat Clin Pract Cardiovasc Med (2009) 6:1

Garcia MJ, Fuster V. An ounce of prevention with a calcium score scan? JACC Cardiovasc Imaging (2009) 2:689-91

Sirol M, Moreno PR, Purushothaman KR, Vucic E, Amirbekian V, Weinmann HJ, Muntner P, Fuster V, Fayad ZA. Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability. Circ Cardiovasc Imaging (2009) 2:391-6

Martin de Francisco AL, Aguilera L, Fuster V. [Cardiovascular, renal and other chronic diseases. Early intervention is necessary in chronic kidney disease] Nefrologia (2009) 29:6-9

Fuster V, van der Zee S, Miller MA. Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 2:398-406